Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)

Barclays PLC raised its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 51.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,306 shares of the company’s stock after buying an additional 11,273 shares during the quarter. Barclays PLC owned about 0.11% of Acrivon Therapeutics worth $233,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. State Street Corp lifted its position in Acrivon Therapeutics by 26.4% during the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after acquiring an additional 47,233 shares during the period. Perceptive Advisors LLC increased its stake in shares of Acrivon Therapeutics by 78.2% during the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock valued at $31,093,000 after purchasing an additional 2,353,000 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Acrivon Therapeutics by 58.8% during the second quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock valued at $5,503,000 after purchasing an additional 351,397 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Acrivon Therapeutics during the second quarter valued at approximately $61,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter worth approximately $58,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Trading Down 2.2 %

ACRV stock opened at $5.65 on Wednesday. The stock’s 50 day simple moving average is $6.53 and its 200 day simple moving average is $7.44. Acrivon Therapeutics, Inc. has a 12-month low of $3.19 and a 12-month high of $11.90. The stock has a market capitalization of $175.94 million, a PE ratio of -2.09 and a beta of 0.77.

Wall Street Analysts Forecast Growth

ACRV has been the subject of a number of analyst reports. BMO Capital Markets reduced their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Acrivon Therapeutics in a report on Thursday, November 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.